EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Epigenetic Aging–Cancer Continuum: Biomarkers, Metabolism, and Therapy

Christos Papaneophytou iD, Myrtani Pieri iD, Maria-Eleni Makreli iD, Evelina Charidemou iD, Eleni P Andreou iD

Genes · 2026

DOI: 10.3390/genes17091130 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Genes, 2026. Verfasst von Christos Papaneophytou und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Life Sciences, School of Life and Health Sciences, University of Nicosia, 2417 Nicosia, Cyprus. Hauptthemen laut MEDLINE: Epigenesis, Genetic, Aging, Neoplasms, Biomarkers, Tumor. Die Arbeit nennt 326 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aging and cancer form a biological continuum influenced by epigenomic changes, metabolic dysfunction, inflammation, cellular senescence, and loss of tissue homeostasis. Age-related epigenetic alterations can promote cancer, which exploits plasticity for evolution, immune evasion, metastasis, and resistance. Nutrition and metabolism affect this process through one-carbon metabolism, methyl-donor availability, acetyl-CoA and NAD+ balance, redox status, microbiome metabolites, and chromatin enzyme activity. Circulating biomarkers such as cell-free DNA methylation, mutation-based ctDNA, fragmentomic features, and non-coding RNAs can detect tumor and host changes linked to aging, inflammation, nutrition, and treatment with minimal invasiveness. This review explores the epigenetic aging–cancer link, how nutrition and metabolism modify pathways, and the potential of circulating biomarkers for diagnosis, prognosis, prediction, and monitoring. The focus is on epigenetic plasticity, drug-tolerant states, resistance, epigenetic drugs, metabolic targeting, and nutritional interventions. New technologies, including single-cell and spatial epigenomics, long-read sequencing, and multimodal computational approaches, aid biomarker discovery and clinical use. Challenges include variability, misclassification, heterogeneity, confounding, reverse causality, overfitting, and limited validation. Clinical applications need standard workflows, representative cohorts, transparent models, and proof that biomarker-guided strategies improve outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epigenesis, GeneticAgingNeoplasmsBiomarkers, TumorHumansDNA MethylationEpigenomics

Stichwörter der Autor:innen

cancercirculating biomarkersepigenetic agingmetabolismnutritiontherapeutic response

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Life Sciences, School of Life and Health Sciences, University of Nicosia, 2417 Nicosia, Cyprus.

ORCID-Profile: Christos Papaneophytou, Myrtani Pieri, Maria-Eleni Makreli, Evelina Charidemou, Eleni P Andreou

Zitieren

APA

Papaneophytou, C., Pieri, M., Makreli, M. E., Charidemou, E., & Andreou, E. P. (2026). The Epigenetic Aging–Cancer Continuum: Biomarkers, Metabolism, and Therapy. Genes. https://doi.org/10.3390/genes17091130

Vancouver

Papaneophytou C, Pieri M, Makreli ME, Charidemou E, Andreou EP. The Epigenetic Aging–Cancer Continuum: Biomarkers, Metabolism, and Therapy. Genes. 2026. doi:10.3390/genes17091130

BibTeX
@article{Papaneophytou2026,
  author = {Papaneophytou, Christos and Pieri, Myrtani and Makreli, Maria-Eleni and Charidemou, Evelina and Andreou, Eleni P},
  title = {The Epigenetic Aging–Cancer Continuum: Biomarkers, Metabolism, and Therapy},
  journal = {Genes},
  year = {2026},
  doi = {10.3390/genes17091130}
}
Kostenlos starten →